Karsten Bruins Slot

The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial

Geoff Cohen, Peter Sandercock, Stefano Ricci, 2012, The Lancet.

Update on the third international stroke trial (IST-3) of thrombolysis for acute ischaemic stroke and baseline features of the 3035 patients recruited

P. Sandercock, G. Hankey, M. Brainin, 2011, Trials.

Risk Factors for Intracranial Hemorrhage in Acute Ischemic Stroke Patients Treated With Recombinant Tissue Plasminogen Activator: A Systematic Review and Meta-Analysis of 55 Studies

Peter Sandercock, Joanna Wardlaw, P. Sandercock, 2012, Stroke.

The third international stroke trial (IST-3) of thrombolysis for acute ischaemic stroke

Peter Sandercock, Joanna Wardlaw, Stefano Ricci, 2008, Trials.

Causes of death by level of dependency at 6 months after ischemic stroke in 3 large cohorts.

P. Dorman, P. Sandercock, S. Lewis, 2009, Stroke.

Effects of alteplase on survival after ischaemic stroke (IST-3): 3 year follow-up of a randomised, controlled, open-label trial

P. Sandercock, J. Wardlaw, R. Lindley, 2016, The Lancet Neurology.

EPITHET—where next?

P. Sandercock, G. Hankey, J. Wardlaw, 2008, The Lancet Neurology.

Factor Xa Inhibitors Versus Vitamin K Antagonists for Preventing Cerebral or Systemic Embolism in Patients With Atrial Fibrillation

E. Berge, Karsten Bruins Slot, K. B. Slot, 2013, Emergencias : revista de la Sociedad Espanola de Medicina de Emergencias.

Thrombolytic treatment for stroke: patient preferences for treatment, information, and involvement.

E. Berge, Karsten Bruins Slot, K. B. Slot, 2009, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

Impact of functional status at six months on long term survival in patients with ischaemic stroke: prospective cohort studies

P. Dorman, P. Sandercock, S. Lewis, 2008, BMJ : British Medical Journal.

Oral anticoagulants versus antiplatelet therapy for preventing stroke and systemic embolic events in patients with atrial fibrillation

P. Koudstaal, E. Berge, M. Aguilar, 2012 .